ArticleBMC infectious diseases2023
Incidence of nontuberculous mycobacteria infections among persons with cystic fibrosis in the United States (2010-2019).
Article in BMC infectious diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.
- Antibiotic treatment for non-tuberculous mycobacteria lung infection in people with cystic fibrosis.The Cochrane database of systematic reviews · 2025Pooled it
- Randomized study of the efficacy, safety, and pharmacokinetics of SPR720 for the treatment of Mycobacterium avium complex pulmonary disease.Scientific reports · 2026Trial
- Evaluation of the drug interaction between rifabutin and elexacaftor/tezacaftor/ivacaftor (ETI).Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2026Trial
- Pharmacokinetics of Omadacycline in Adults with Cystic Fibrosis.Clinical pharmacokinetics · 2024Trial
- Temperature and pH growth preferences predict the pathogenicity and environmental distributions of nontuberculous mycobacteria.mSystems · 2026Article
- Clinical features of nontuberculous mycobacteria and diagnosis with nanopore targeted sequencing: a retrospective cohort study.Annals of clinical microbiology and antimicrobials · 2026Article
- Clofazimine use for nontuberculous mycobacterial infections: 10-year experience in Belgium.BMC pulmonary medicine · 2026Observational
- Hospital Environment-Associated Sources of Mycobacterium abscessus Infection in Transplant Recipients.JAMA network open · 2026Article
- Nontuberculous Mycobacteria Pulmonary Disease Prevalence, New York City, 2012 to 2020.CHEST pulmonary · 2026Article
- Investigating the Antimycobacterial, Antibiofilm, and Antioxidant Activities of Plant Extracts AgainstMicroorganisms · 2026Article
- Pulmonary nontuberculous mycobacterial infection is associated with urinary molybdenum concentrations in a bronchiectasis cohort.Environmental epidemiology (Philadelphia, Pa.) · 2026Article
- From colonisation to chronicity: adaptation ofMicrobiology (Reading, England) · 2026Article
- The risk of NTM pulmonary infection associated with trace metal exposure from public distribution system water in the United States.Journal of exposure science & environmental epidemiology · 2026Article
- Large-scale testing of antimicrobial lethality at single-cell resolution predicts mycobacterial infection outcomes.Nature microbiology · 2026Article
- Non-tuberculous mycobacterial infection in cystic fibrosis before and after initiation of elexacaftor/tezacaftor/ivacaftor: now is not the time to lower the guard.BMJ open respiratory research · 2025Observational
- Sex-Associated Radiographic and Clinical Differences in Nontuberculous Mycobacteria Pulmonary Disease.Chronic obstructive pulmonary diseases (Miami, Fla.) · 2025Article
- Factors predicting incidence of nontuberculous mycobacteria in an era of climate change and altered ecosystems in the United States.The Science of the total environment · 2025Article
- The Epidemiology of Nontuberculous Mycobacteria in Cystic Fibrosis.Children (Basel, Switzerland) · 2025Review
- The growing impact of nontuberculous mycobacteria: A multidisciplinary review of ecology, pathogenesis, diagnosis, and treatment.Infectious medicine · 2025Review
- In Vitro Activity of Imipenem/Relebactam Alone and in Combination Against Cystic Fibrosis Isolates ofAntibiotics (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNontuberculous mycobacteria (NTM) are ubiquitous, environmental bacteria that can cause chronic lung disease. Persons with cystic fibrosis (pwCF) are at high risk for NTM. Approximately 1 in 5 pwCF in the United States (U.S.) is affected by pathogenic NTM species, and incidence rates of NTM have been increasing among pwCF as well as in the general population. Prevalence of NTM pulmonary infections (PI) varies widely across the United States because of geographic variation in environmental exposures. This study will present updated region-level incidence of NTM infections in the cystic fibrosis (CF) population in the U.S.
methodsWe used the Cystic Fibrosis Foundation Patient Registry (CFFPR) data for the period 2010 through 2019. Our study population comprised persons with CF ≥ 12 years of age who had been tested for NTM PI. We included only registry participants with NTM culture results. We defined incident cases as persons with one positive mycobacterial culture preceded by ≥ two negative mycobacterial cultures. We defined non-cases as persons with ≥ two negative mycobacterial cultures. We estimated average annual NTM PI incidence by region. Using quasi-Poisson models, we calculated annual percent change in incidence by region.
resultsWe identified 3,771 incident NTM infections. Of these cases, 1,816 (48.2%) were Mycobacterium avium complex (MAC) infections and 960 (25.5%) were Mycobacterium abscessus infections. The average annual incidence of NTM PI among pwCF in the U.S. was 58.0 cases per 1,000 persons. The Northeast had the highest incidence of MAC (33.5/1,000 persons tested) and the South had the highest incidence of M. abscessus (20.3/1,000 persons tested). From 2010 to 2019, the annual incidence of total NTM PI increased significantly by 3.5% per year in the U.S.
conclusionsNTM PI incidence is increasing among pwCF. Identifying high risk areas and increasing trends is important for allocating public health and clinical resources as well as evaluating interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.